CXCL8 and cystic fibrosis: The delivery of agomiRNAs-inhibiting IL-8 is of great interest for the development of therapeutic protocols for (a) down-regulating the hyperinflammatory condition of patients with Cystic Fibrosis [107,108], or (b) interfering with the COVID-19 “cytokine storm” [109,110].